Panel Hears Oral Arguments in CRISPR Patent Battle Royal

The latest skirmish in the dispute over who invented CRISPR technology played out Tuesday before a three-judge panel of the Patent Trial and Appeal Board (PTAB) in Alexandria, VA

Getting Bioprocessing Up to Speed

The key to increasing the efficiency of bioprocessing is developing robust platform processes with enhanced productivity and recovery that maintain safety and quality profiles.

Audentes Therapeutics Acquires Cardiogen Sciences

Buyer adds to its gene therapy holdings with a third preclinical program, CASQ2-CPVT, which it plans to 'rapidly' advance into the clinic
A natural human enzyme has been harnessed to create a process that can lengthen oligonucleotide chains repetitively. The new process may be able to generate synthetic DNA more quickly

Synthetic DNA as Easy as 1-2-3 with One-and-Done Enzymes

The best enzyme for de novo DNA synthesis may be one that is denied all its enzymatic attributes. Yes, it acts on a specific...

Gene Editing 2.0: Find-and-Replace Feature Works Genome-Wide

Scientists use codon-swapping techniques to create genomically recoded organisms, pointing to safer and more chemically flexible biotechnology applications.

Gene Drive Control Worry Eased by Genetic Neutralizing Elements

CRISPR-Cas9-based tools that control the balance of genetic inheritance, known as gene drives, could reduce the burden of mosquito-borne infectious diseases. But their ability to efficiently spread throughout a target population raises concerns regarding their lack of control in the wild. Now, researchers have developed two active, guide RNA-only, genetic neutralizing elements that act as a mechanism of control by halting or deleting gene drives.

CRISPR-Clean Pig Genome Could Mean Safer Pig-to-Human Transplants

CRISPR-Cas9 achieves genome-wide inactivation of endogenous retroviruses in pig genome, hastens development of human-transplant-ready pig organs.

GE Healthcare Life Sciences, Sigma-Aldrich License CRISPR/Cas9 Patents

Broad Institute of MIT and Harvard inks non-exclusive agreements granting access to the gene editing system

CRISPR Companies Ink IP Collaboration with Charpentier-UC Patent Holders

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics come to terms with University of California, Emmanuelle Charpentier, Ph.D., and the University of Vienna

Voyager Licenses ReGenX’ NAV Vectors to Develop CNS Disease Gene Therapies

Voyager Therapeutics has entered a license agreement with ReGenX to use the gene therapy firm's NAV® vectors to develop and commercialize gene therapies to treat ALS, Friedreich's ataxia, and Huntington's disease.